Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
VKTX has been in the news recently: Viking Therapeutics' shares dropped 42% following disappointing Phase 2 trial results for its obesity drug, VKTX, which had a high dropout rate of 20% due to side effects. Despite this setback, the company has attracted interest from financial giants, as indicated by unusual options trades suggesting a bullish outlook.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
